These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 1852156)

  • 41. [A manifesting carrier of Duchenne muscular dystrophy presenting mosaic distribution of dystrophin negative and positive muscle fibers].
    Kikumoto O; Yoshinaga J; Sasaki T; Ideshita H; Hikiji A; Arahata K
    Rinsho Shinkeigaku; 1990 Jan; 30(1):107-9. PubMed ID: 2184962
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pyruvate-kinase (PK) and creatine-kinase (CK) in normal pregnancy and its implication in genetic counseling of Duchenne muscular dystrophy (DMD).
    Zatz M; Karp LE; Rogatko A
    Am J Med Genet; 1982 Nov; 13(3):257-62. PubMed ID: 7180871
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Systolic time interval characteristics in children with Duchenne's progressive muscular dystrophy.
    Sanyal SK; Tierney RC; Rao PS; Pitner SE; George SL; Givins DR
    Pediatrics; 1982 Dec; 70(6):958-64. PubMed ID: 7145553
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of chronic administration of verapamil in Duchenne muscular dystrophy.
    García AM; Goldemberg AL; Fernández H; Fortunato M; Ricci L; Trucco RE
    Gen Pharmacol; 1990; 21(6):939-42. PubMed ID: 2177715
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [The strength and functional performance of patients with Duchenne muscular dystrophy based on natural history].
    Lue YJ; Jong YJ; Lin YT; Chen SS
    Gaoxiong Yi Xue Ke Xue Za Zhi; 1992 Nov; 8(11):597-604. PubMed ID: 1296040
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Regularity in the change of serum creatine kinase level in Duchenne muscular dystrophy. A study with long-term follow-up cases.
    Konagaya M; Takayanagi T
    Jpn J Med; 1986 Feb; 25(1):2-8. PubMed ID: 3712859
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of chronic treatment with the calcium antagonist diltiazem in Duchenne muscular dystrophy.
    Bertorini TE; Palmieri GM; Griffin JW; Igarashi M; McGee J; Brown R; Nutting DF; Hinton AB; Karas JG
    Neurology; 1988 Apr; 38(4):609-13. PubMed ID: 3281058
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Regeneration in Duchenne muscular dystrophy. Electromyographic evidence.
    Desmedt JE; Borenstein S
    Arch Neurol; 1976 Sep; 33(9):642-50. PubMed ID: 962646
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Malignant hyperthermia in Duchenne muscular dystrophy.
    Brownell AK; Paasuke RT; Elash A; Fowlow SB; Seagram CG; Diewold RJ; Friesen C
    Anesthesiology; 1983 Feb; 58(2):180-2. PubMed ID: 6824172
    [No Abstract]   [Full Text] [Related]  

  • 50. Selenium and vitamin E treatment of Duchenne muscular dystrophy: no effect on muscle function.
    Bäckman E; Nylander E; Johansson I; Henriksson KG; Tagesson C
    Acta Neurol Scand; 1988 Nov; 78(5):429-35. PubMed ID: 3218450
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Decrease in urinary excretion of 3-methylhistidine by patients with Duchenne muscular dystrophy during glucocorticoid treatment.
    Kawai H; Adachi K; Nishida Y; Inui T; Kimura C; Saito S
    J Neurol; 1993; 240(3):181-6. PubMed ID: 8482992
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term benefit from prednisone therapy in Duchenne muscular dystrophy.
    Fenichel GM; Florence JM; Pestronk A; Mendell JR; Moxley RT; Griggs RC; Brooke MH; Miller JP; Robison J; King W
    Neurology; 1991 Dec; 41(12):1874-7. PubMed ID: 1745340
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Purine metabolism in Duchenne muscular dystrophy.
    de Bruyn CH; Kulakowski S; van Bennekom CA; Renoirte P; Müller MM
    Adv Exp Med Biol; 1980; 122A():177-82. PubMed ID: 7424633
    [No Abstract]   [Full Text] [Related]  

  • 54. Creatine kinase and prostaglandin E2 release from isolated Duchenne muscle.
    Jackson MJ; Brooke MH; Kaiser K; Edwards RH
    Neurology; 1991 Jan; 41(1):101-4. PubMed ID: 1845917
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical investigation of Duchenne muscular dystrophy. A methodology for therapeutic trials based on natural history controls.
    Mendell JR; Province MA; Moxley RT; Griggs RC; Brooke MH; Fenichel GM; Miller JP; Kaiser KK; King W; Robison J
    Arch Neurol; 1987 Aug; 44(8):808-11. PubMed ID: 3115236
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of dantrolene sodium in myotonic dystrophy.
    Mamoli B; Dal-Bianco P; Zeitlhofer K
    Eur Neurol; 1983; 22(1):29-34. PubMed ID: 6840139
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Resveratrol improves motor function in patients with muscular dystrophies: an open-label, single-arm, phase IIa study.
    Kawamura K; Fukumura S; Nikaido K; Tachi N; Kozuka N; Seino T; Hatakeyama K; Mori M; Ito YM; Takami A; Hinotsu S; Kuno A; Kawasaki Y; Horio Y; Tsutsumi H
    Sci Rep; 2020 Nov; 10(1):20585. PubMed ID: 33239684
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dantrolene enhances antisense-mediated exon skipping in human and mouse models of Duchenne muscular dystrophy.
    Kendall GC; Mokhonova EI; Moran M; Sejbuk NE; Wang DW; Silva O; Wang RT; Martinez L; Lu QL; Damoiseaux R; Spencer MJ; Nelson SF; Miceli MC
    Sci Transl Med; 2012 Dec; 4(164):164ra160. PubMed ID: 23241744
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Non-canonical Molecular Targets for Novel Analgesics: Intracellular Calcium and HCN Channels.
    Cook DC; Goldstein PA
    Curr Neuropharmacol; 2021; 19(11):1937-1951. PubMed ID: 33463473
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeting RyR Activity Boosts Antisense Exon 44 and 45 Skipping in Human DMD Skeletal or Cardiac Muscle Culture Models.
    Barthélémy F; Wang RT; Hsu C; Douine ED; Marcantonio EE; Nelson SF; Miceli MC
    Mol Ther Nucleic Acids; 2019 Dec; 18():580-589. PubMed ID: 31678734
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.